NEW YORK – With the launch last week of its PrecivityAD test, C2N Diagnostics has become the first company to bring a blood-based test for Alzheimer's to market.
The company anticipates that the test, which uses mass spectrometry to measures levels of amyloid beta (Aβ) and apolipoprotein E in patient blood, will see uptake among physicians looking for additional information to evaluate patients they suspect of having Alzheimer's, and drug companies in need of a quick and relatively inexpensive test for selecting subjects for clinical trials.